Brief: Windtree Announces Results From Its Phase 2 Study Of Lucinactant For Covid-19 Associated Acute Respiratory Distress Syndrome And Lung Injury
22/03/2022 11:48
March 22 (Reuters) - Windtree Therapeutics Inc WINT.O :
* WINDTREE ANNOUNCES RESULTS FROM ITS PHASE 2 STUDY OF
LUCINACTANT
FOR COVID-19 ASSOCIATED ACUTE RESPIRATORY DISTRESS SYNDROME
(ARDS) AND LUNG INJURY
* WINDTREE THERAPEUTICS - TRIAL DEMONSTRATED INTRATRACHEAL
ADMINISTRATION OF RECONSTITUTED LYOPHILIZED LUCINACTANT WAS
GENERALLY SAFE AND WELL TOLERATED
Source text for Eikon: ID:nGNX8HQPrF
Further company coverage: WINT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Windtree Therapeutics
See all newsBrief: Windtree Therapeutics Announces It Has Signed A Letter Of Intent To Acquire Commloan
Brief: Windtree Therapeutics Announces It May Receive License Agreement Payments From Its Licensee For Renewed Acute Pulmonary Development By The Licensee
Brief: Windtree Therapeutics Stockholders Approve Key Proposals For Revenue And Profit Generation At The Special Stockholder Meeting
Brief: Windtree Therapeutics Terminates Seismic-C Clinical Study At 20 Enrollments - SEC Filing
Brief: Windtree Therapeutics Inc - Announces Interim Analysis Of Istaroxime Phase 2 Study